CorMedix Announces Commercial Agreement With Top Tier Dialysis Provider For The Supply Of DefenCath
Portfolio Pulse from Benzinga Newsdesk
CorMedix Inc. (NASDAQ:CRMD) has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for its product DefenCath. The company received NDA approval for DefenCath on November 15, 2023, and began commercialization in the inpatient setting on April 15th. Outpatient commercialization is expected to start in July, expanding access to over 500 dialysis facilities nationwide.
May 28, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CorMedix Inc. has secured a multi-year commercial supply contract for DefenCath with a top tier midsized dialysis provider. This agreement follows recent NDA approval and inpatient commercialization, with outpatient commercialization set to begin in July.
The multi-year supply contract with a top tier dialysis provider is a significant milestone for CorMedix, indicating strong demand and potential revenue growth. The expansion to over 500 facilities will likely boost sales and market presence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100